These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23241899)

  • 1. What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
    Fournié JJ; Sicard H; Poupot M; Bezombes C; Blanc A; Romagné F; Ysebaert L; Laurent G
    Cell Mol Immunol; 2013 Jan; 10(1):35-41. PubMed ID: 23241899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.
    Marquez-Medina D; Salla-Fortuny J; Salud-Salvia A
    Clin Transl Oncol; 2012 Dec; 14(12):891-5. PubMed ID: 23054752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing γδ T cells in anticancer immunotherapy.
    Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
    Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
    Miyashita M; Shimizu T; Ashihara E; Ukimura O
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γδ T cells as critical anti-tumor immune effectors.
    Arias-Badia M; Chang R; Fong L
    Nat Cancer; 2024 Aug; 5(8):1145-1157. PubMed ID: 39060435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. γδ T-cell immunotherapy for lung cancer.
    Yoshida Y; Nakajima J; Wada H; Kakimi K
    Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.
    Legut M; Cole DK; Sewell AK
    Cell Mol Immunol; 2015 Nov; 12(6):656-68. PubMed ID: 25864915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How tumors might withstand γδ T-cell attack.
    Capietto AH; Martinet L; Fournié JJ
    Cell Mol Life Sci; 2011 Jul; 68(14):2433-42. PubMed ID: 21547501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.
    Liu Y; Zhang C
    Cells; 2020 May; 9(5):. PubMed ID: 32413966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies.
    Sebestyen Z; Prinz I; Déchanet-Merville J; Silva-Santos B; Kuball J
    Nat Rev Drug Discov; 2020 Mar; 19(3):169-184. PubMed ID: 31492944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [γδ T cell-based cancer immunotherapy].
    Matsushita H; Kakimi K
    Nihon Rinsho; 2017 Feb; 75(2):301-305. PubMed ID: 30562868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
    Rei M; Pennington DJ; Silva-Santos B
    Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
    Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
    Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
    Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
    Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
    Liu Z; Guo B; Lopez RD
    J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γδ T-cell conference 2012: close encounters for the fifth time.
    Silva-Santos B; Schamel WW; Fisch P; Eberl M
    Eur J Immunol; 2012 Dec; 42(12):3101-5. PubMed ID: 23255005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with γδ T-cells: the future is there.
    Kabelitz D; Yin Z
    Immunotherapy; 2024; 16(11):705-708. PubMed ID: 38940301
    [No Abstract]   [Full Text] [Related]  

  • 20. γδ T Cells: The Ideal Tool for Cancer Immunotherapy.
    Yazdanifar M; Barbarito G; Bertaina A; Airoldi I
    Cells; 2020 May; 9(5):. PubMed ID: 32456316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.